Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 8/7/2020 4:56:57 AM - Followers: 188 - Board type: Free - Posts Today: 0

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.  https://www.massdevice.com/neovasc-shares-surge-45-affirmed-tiara-patent-case-decision-edwards/

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of SeekingAlpha.com)
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 
SOURCE:  http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,579,964.PN.&OS=PN/8,579,964&RS=PN/8,579,964

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ 


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of NASDAQ.com 
Updated: April 1st, 2018:   STRONG BUY.
Source: https://www.nasdaq.com/symbol/nvcn/analyst-research

STRONG BUY                                  
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer (6-k) 09/25/2020 06:04:35 AM
NVCN News: Notice of Effectiveness (effect) 09/15/2020 06:18:58 AM
NVCN News: Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference 09/08/2020 05:00:10 PM
NVCN News: Report of Foreign Issuer (6-k) 09/03/2020 05:12:44 PM
NVCN News: Neovasc Inc. Reports Results of Annual General Meeting of Shareholders 09/03/2020 04:34:09 PM
#11825   https://photos.app.goo.gl/4QRRzemsNqZyYRoT6 Steve Miller 08/07/20 04:56:57 AM
#11824   More news out today - 6K LutherTiggs 07/09/20 08:00:15 AM
#11823   Boston scientific gets approval on another device and zeusgodmd 06/29/20 12:12:46 PM
#11822   Great news on Reducer! LutherTiggs 06/26/20 11:39:47 AM
#11821   Good point. I think this closes on June 3. ravmn 05/30/20 11:43:34 AM
#11820   Boston scientific raised 2 billion dollars last time zeusgodmd 05/28/20 07:06:37 AM
#11819   The only scenario that I can conceive why Crapola2theleft 04/21/20 03:47:24 PM
#11818   yes, but wrong direction lister 04/21/20 11:00:40 AM
#11817   Started the run? rrao11 04/15/20 10:47:00 AM
#11816   * * $NVCN Video Chart 04-14-2020 * * ClayTrader 04/14/20 06:23:22 PM
#11815   Luther... I hope you've got that right? Crapola2theleft 04/14/20 01:51:04 PM
#11814   Somebody definitely knows something. rrao11 04/14/20 12:25:22 PM
#11813   Just moved into on of biggest gainer on zeusgodmd 04/14/20 12:25:12 PM
#11812   Company please fill us in looks like they zeusgodmd 04/14/20 12:20:54 PM
#11811   This is not hardly any volume should be zeusgodmd 04/14/20 11:50:29 AM
#11810   Hope in this case it becomes "buy" on LutherTiggs 04/14/20 11:19:33 AM
#11809   Shorts must be coving with no shares zeusgodmd 04/14/20 10:11:43 AM
#11808   Thank you!!! zeusgodmd 04/14/20 10:10:10 AM
#11807   32 cent spike after hours news tomorrow zeusgodmd 04/13/20 08:59:45 PM
#11806   The people in the know probably know fda zeusgodmd 04/13/20 12:52:11 PM
#11805   I currently don’t mind have a ton if zeusgodmd 04/02/20 12:04:24 PM
#11804   Whoops I should have said "Next day he Crapola2theleft 04/02/20 11:33:48 AM
#11803   zeus... Don't forget Fred retired from BSX as Crapola2theleft 04/02/20 11:29:58 AM
#11802   Not sure why this company does not sell zeusgodmd 04/02/20 10:37:37 AM
#11801   I think old folks that survive this will zeusgodmd 04/01/20 10:37:57 AM
#11800   priority corona lister 04/01/20 10:12:41 AM
#11799   Nice transparency. Will need some money soon zeusgodmd 03/30/20 06:25:26 PM
#11798   Fred should post that the corona virus is zeusgodmd 03/27/20 10:21:51 PM
#11797   Fred has been very very quiet. ravmn 03/21/20 12:00:38 AM
#11796   We see next time many share sales due lister 03/20/20 03:20:16 PM
#11795   Never Post... I've looked ( all in the Crapola2theleft 03/19/20 06:18:40 PM
#11794   We should hear about an extension soon. The ravmn 03/08/20 07:29:06 PM
#11793   VANCOUVER and MINNEAPOLIS, February 20, 2020 – Neovasc, lister 02/29/20 03:53:49 AM
#11792   how many shares are listed? lister 02/29/20 03:19:31 AM
#11791   you are right but if and when. Are lister 02/29/20 03:16:58 AM
#11790   Don’t forget. The $3bil market was only rrao11 02/28/20 03:55:11 AM
#11789   I just listened to Freds remarks from Wednesday. ravmn 02/27/20 09:04:24 PM
#11788   Guessing does not cost anything. Never_Post 02/27/20 08:18:37 PM
#11787   lister... If the FDA, comes out, I see Crapola2theleft 02/27/20 02:41:40 PM
#11786   I see this stock at $2 in four weeks lister 02/27/20 02:07:16 PM
#11785   Never... Disagree! Way toooo much money in this Crapola2theleft 02/27/20 01:10:57 PM
#11784   I actually expect the Big Boys to Bid Never_Post 02/27/20 10:26:49 AM
#11783   Never... Yes, of course your right. Just waiting Crapola2theleft 02/26/20 09:50:54 PM
#11782   IMO - The Deal is done! Never_Post 02/26/20 08:35:39 PM
#11781   Nicer! Hit 3.01 and 23rd new high-eom Never_Post 02/20/20 02:10:39 PM
#11780   Nice! Hit $3.00 and 22nd new high today Never_Post 02/20/20 02:08:21 PM
#11779   NVCN looking good this morning. PR indicates Never_Post 02/20/20 11:21:21 AM
#11778   Technically it would be too early but you Never_Post 02/19/20 11:18:38 AM
#11777   Anyone think this gets approved in 60 days ravmn 02/18/20 05:31:14 PM
#11776   Makes sense, thanks. lenny_squiggy 02/11/20 01:58:52 PM
Consent Preferences